Return to search

Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity

No / The identification of an agent that is selectively activated by a cytochrome P450 (CYP) has the potential for tissue specific dose intensification as a means of significantly improving its therapeutic value. Towards this goal, we disclose evidence for the pathway of activation of a duocarmycin analogue, ICT2700, which targets CYP1A1 for biological activity.

Identiferoai:union.ndltd.org:BRADFORD/oai:bradscholars.brad.ac.uk:10454/6138
Date January 2011
CreatorsPors, Klaus, Loadman, Paul, Shnyder, Steven, Sutherland, Mark, Sheldrake, Helen M., Guino, M., Kiakos, K., Hartley, J.A., Searcey, M., Patterson, Laurence H.
Source SetsBradford Scholars
LanguageEnglish
Detected LanguageEnglish
TypeArticle, No full-text in the repository

Page generated in 0.0015 seconds